BCL2 and cancer: While known driver mutations in MYB and the activation of Notch are not actionable targets right now, we have identified the BCL2 gene overexpression solely in LGACC cancer cells that has small molecular inhibitors including Gossypol and Disarib [49,50,51,52,53].